Interventional treatment of neuroendocrine liver metastases

Neuroendocrine gastroenteropancreatic tumours are rare with an incidence of 2–4/100.000 per year. More than 75% of the patients develop hepatic metastases, which reduce the five year survival from 70–80% to 30–40%. In addition to chemo- and biotherapy, interventional therapy of liver metastases shou...

Ausführliche Beschreibung